Public Joint-Stock Company "Human Stem Cells Institute"

Total Valuation

Public Joint-Stock Company "Human Stem Cells Institute" carries a market capitalization of 3.07B, placing it among publicly traded companies globally. Its enterprise value stands at 1.41B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Public Joint-Stock Company "Human Stem Cells Institute" currently has 75.00M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 3.47, and the price-to-book ratio stands at 17.07.

Enterprise Valuation

On an enterprise value basis, Public Joint-Stock Company "Human Stem Cells Institute" trades at an EV/EBITDA multiple of 515.60 and an EV/FCF ratio of 17.24. The EV/Sales ratio of 3.60 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 515.60 provides insight into valuation relative to core operating earnings.

Financial Position

Public Joint-Stock Company "Human Stem Cells Institute" maintains a current ratio of 1.18, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 145.10, indicating elevated leverage, while an interest coverage ratio of -5.06 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Public Joint-Stock Company "Human Stem Cells Institute"'s stock has declined approximately -51.11804% over the past 52 weeks. The 50-day moving average sits at 77.10, while the 200-day moving average is 77.10.

Income Statement

Over the trailing twelve months, Public Joint-Stock Company "Human Stem Cells Institute" generated 390.36M in revenue and converted that into -111.31M in net income, yielding earnings per share of -1.75. EBITDA reached -136.91M, while operating income came in at -136.91M.

Balance Sheet

Public Joint-Stock Company "Human Stem Cells Institute" holds 378.06M in cash and equivalents against 346.25M in total debt, resulting in a net debt position of 60.71M. Total book value stands at 79.31M, with working capital of 84.47M providing operational flexibility.

Cash Flow

Public Joint-Stock Company "Human Stem Cells Institute" produced 57.93M in operating cash flow over the past twelve months.

Margins

Public Joint-Stock Company "Human Stem Cells Institute" operates with a gross margin of 75.00, reflecting its pricing power and cost economics. The operating margin of -35.07 and net profit margin of -28.51 provide insight into operational efficiency.

Dividends & Yields

Scores

Public Joint-Stock Company "Human Stem Cells Institute" posts an Altman Z-Score of 1.16, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.